(Circulation. 1997;96:2877-2883.)
© 1997 American Heart Association, Inc.
Articles |
Differential Effects of Anticoagulants on the Activation of Platelets Ex Vivo
From the Department of Medicine (D.J.S., B.E.S.) and the Department of Biochemistry (P.B.T., K.G.M.), the University of Vermont College of Medicine, Burlington.
Correspondence to David J. Schneider, MD, Cardiovascular Division, E217 Given Bldg, University of Vermont, Burlington, VT 05405. E-mail djschnei{at}zoo.uvm.edu
Background Because activation of platelets and of the coagulation system are interdependent mediators of thrombosis, platelet activation was characterized in whole blood in the presence of anticoagulants used to assess platelet function in vitro or as treatment for patients with occlusive arterial disease.
Methods and Results Blood was anticoagulated alone or in combination with citrate, ethylenediaminetetraacetatic acid, corn trypsin inhibitor (CTI, an inhibitor of activated factor XII), heparin, enoxaparin, recombinant tick anticoagulant peptide (rTAP), or recombinant hirudin. Platelet activation in response to adenosine diphosphate (ADP) or collagen was detected by assay of P-selectin on the platelet surface delineated by flow cytometry. Although minimal activation was seen without ADP, the fraction of platelets expressing P-selectin in response to ADP was greatest in blood anticoagulated with citrate compared with CTI and all other anticoagulants. ADP-induced platelet activation was greater in blood anticoagulated with heparin compared with an equipotent anti-Xa concentration of enoxaparin. More variable results were seen with collagen, but platelet activation in the presence of citrate was greater than that with CTI.
Conclusions Interpretation of assays of inhibition of platelet activation by potentially therapeutic agents in vitro requires consideration of the effects of anticoagulants used. In addition, anticoagulants other than standard heparin may potentiate efficacy of antiplatelet drugs.
Key Words: platelets • occlusion • coagulation • arteriosclerosis
This article has been cited by other articles:
 |
|
 |
|
  P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. V. Mohan, D. P. Mikhailidis, and G. P. Stansby Platelet Activation in Bypass Surgery for Critical Limb Ischemia Vascular and Endovascular Surgery, September 1, 2007; 41(4): 322 - 329. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Schneider On Defining Aspirin Resistance J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1710 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
B. Labarthe, P. Theroux, M. Angioi, and M. Ghitescu Matching the Evaluation of the Clinical Efficacy of Clopidogrel to Platelet Function Tests Relevant to the Biological Properties of the Drug J. Am. Coll. Cardiol., August 16, 2005; 46(4): 638 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Chen, H.-W. Chang, S.-S. Juang, H.-K. Yip, and C.-J. Wu Increased Plasma Levels of Soluble P-Selectin in Rheumatic Mitral Stenosis Chest, July 1, 2004; 126(1): 54 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aggarwal, D. A. Whitaker, J. M. Rimmer, R. J. Solomon, F. J. Gennari, B. E. Sobel, and D. J. Schneider Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1559 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Andre, T. LaRocca, S. M. Delaney, P. H. Lin, D. Vincent, U. Sinha, P. B. Conley, and D. R. Phillips Anticoagulants (Thrombin Inhibitors) and Aspirin Synergize With P2Y12 Receptor Antagonism in Thrombosis Circulation, November 25, 2003; 108(21): 2697 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. von Kanel and J. E. Dimsdale Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease Chest, November 1, 2003; 124(5): 1956 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shigeta, N. Taniguchi, K. Omoto, S. Madoiwa, Y. Sakata, M. Mori, K. Hatake, and K. Itoh In Vitro Platelet Activation by an Echo Contrast Agent J. Ultrasound Med., April 1, 2003; 22(4): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Kabbani, M. W. Watkins, T. Ashikaga, E. F. Terrien, P. A. Holoch, B. E. Sobel, and D. J. Schneider Platelet Reactivity Characterized Prospectively: A Determinant of Outcome 90 Days After Percutaneous Coronary Intervention Circulation, July 10, 2001; 104(2): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Amin, S. Ahmad, J. M. Walenga, D. A. Hoppensteadt, H. Leitz, and J. Fareed Soluble P-Selectin in Human Plasma: Effect of Anticoagulant Matrix and its Levels in Patients With Cardiovascular Disorders Clinical and Applied Thrombosis/Hemostasis, April 1, 2000; 6(2): 71 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J Schneider, D. J Taatjes, and B. E Sobel Paradoxical inhibition of fibrinogen binding and potentiation of {alpha}-granule release by specific types of inhibitors of glycoprotein IIb-IIIa Cardiovasc Res, January 14, 2000; 45(2): 437 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Schneider, D. J. Taatjes, D. B. Howard, and B. E. Sobel Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein:: a potential contributor to cardiovascular risk J. Am. Coll. Cardiol., January 1, 1999; 33(1): 261 - 266. [Abstract] [Full Text] [PDF]
|
|